Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06457139 · ClinicalTrials.gov registry record · NA

Preventing T2DM After GDM With Immediate Postpartum Screening

A NA study of Type 2 Diabetes and Gestational Diabetes, sponsored by University of Massachusetts, Worcester.

Recruiting
Registry status
NA
Development phase
116
Enrollment target
1
Study location

NCT06457139 is a NA study of Type 2 Diabetes and Gestational Diabetes that is actively recruiting participants, run by University of Massachusetts, Worcester. The registered enrollment target is 116 participants, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06457139, a NA study of Type 2 Diabetes and Gestational Diabetes, is actively recruiting participants, sponsored by University of Massachusetts, Worcester.

RECRUITING
Registry status
NA
Development phase
116 participants
Enrollment target
1
Study location

Study Summary

The overall goal of this proposal is to create and test an implementation protocol for in-hospital immediate postpartum diabetes screening for postpartum patients with pregnancies affected by GDM.

Interventions

  • DIAGNOSTIC_TEST Glucose tolerance test (2 hour)
  • OTHER Active Comparator

Study Locations (1)

Massachusetts

  • University of Massachusetts Memorial Medical Center - Worcester

Trial Details

FieldValue
Enrollment Target 116 participants
Start Date 2025-06-01
Est. Completion 2028-12-01
Phase NA

What the Registry Record Tells You About NCT06457139

The ClinicalTrials.gov registry entry for NCT06457139 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (89% lower). The listed sponsor is University of Massachusetts, Worcester, which has 240 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Glucose tolerance test (2 hour) is the first listed.

NCT06457139 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06457139 about?

NCT06457139 is a clinical study titled "Preventing T2DM After GDM With Immediate Postpartum Screening". The overall goal of this proposal is to create and test an implementation protocol for in-hospital immediate postpartum diabetes screening for postpartum patients with pregnancies affected by GDM.

What is the current status of trial NCT06457139?

This trial is currently recruiting. It is a NA study. The enrollment target is 116 participants. The study started on 2025-06-01. Estimated completion is 2028-12-01.

What conditions does trial NCT06457139 study?

This clinical trial studies the following conditions: Type 2 Diabetes, Gestational Diabetes.

What interventions are being tested in trial NCT06457139?

The interventions under investigation include: Glucose tolerance test (2 hour) (DIAGNOSTIC_TEST), Active Comparator (OTHER).

Who is sponsoring clinical trial NCT06457139?

This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06457139 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.